This educational program outlines the importance of evolving clinical care models in response to increased life expectancy and variability in individual patient experiences, particularly in the context of sickle cell disease (SCD). It emphasizes the need for personalized and adaptive care models, in which the patient should play a central role, and the need for collaborative networks of physicians and caregivers, taking into account the multisystemic nature of the disease. The proposal also discusses the role of personalized medicine and technological advances, highlighting the need for a shared medical record; the balance between rare center expertise and widespread dissemination of knowledge; and the challenges in high- and low-income countries. It emphasizes the need to move toward personalized medicine, given the significant interindividual variability in both follow-up and treatment, and the introduction of more appropriate biomarkers and predictive algorithms to aid decision-making. The proposal includes real-world examples of successful adaptation in clinical care models. It concludes with a summary of the importance and benefits of evolving clinical care models and a future outlook on the evolution of clinical care in response to demographic changes. These proposals are intended to provide a comprehensive overview of the current state and future directions of clinical care models for SCD.

1.
CDC
.
Data and statistics on sickle cell disease
.
Sickle Cell Disease (SCD)
. Accessed
24
October
2024
https://www.cdc.gov/sickle-cell/data/index.html.
2.
Arlet
J-B
,
Herquelot
E
,
Lamarsalle
L
,
Raguideau
F
,
Bartolucci
P.
Impact of hospitalized vaso-occlusive crises in the previous calendar year on mortality and complications in adults with sickle cell disease: a French population- based study
.
Lancet Reg Health Eur
.
2024
;
40
:
100901
.
3.
Thomson
AM
,
McHugh
TA
,
Oron
AP
, et al.
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021
.
Lancet Haematol
.
2023
;
10
(
8
):
e585
-
e599
.
4.
Calhoun
C
,
Luo
L
,
Baumann
AA
, et al.
Transition for adolescents and young adults with sickle cell disease in a US midwest urban center: a multilevel perspective on barriers, facilitators, and future directions
.
J Pediatr Hematol Oncol
.
2022
;
44
(
5
):
e872
-
e880
.
5.
Sheppard
S
,
Hellemann
G
,
Lebensburger
J
,
Kanter
J.
Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program
.
Pediatr Blood Cancer
.
2023
;
70
(
4
):
e30160
.
6.
Lubeck
D
,
Agodoa
I
,
Bhakta
N
, et al.
Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease
.
JAMA Netw Open
.
2019
;
2
(
11
):
e1915374
.
7.
Gardner
K
,
Douiri
A
,
Drasar
E
, et al.
Survival in adults with sickle cell disease in a high-income setting
.
Blood
.
2016
;
128
(
10
):
1436
-
1438
.
8.
Jiao
B
,
Johnson
KM
,
Ramsey
SD
, et al.
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries
.
Blood Adv
.
2023
;
7
(
13
):
3276
-
3283
.
9.
Pellegrini
M
,
Chakravorty
S
,
del Mar Manu Pereira
M
, et al.
Sickle cell disease: embedding patient participation into an international conference can transform the role of lived experience
.
Orphanet J Rare Dis
.
2023
;
18
(
1
):
341
.
10.
Chakravorty
S
,
Tallett
A
,
Witwicki
C
, et al.
Patient-reported experience measure in sickle cell disease
.
Arch Dis Child
.
2018
;
103
(
12
):
1104
-
1109
.
11.
Piel
FB
,
Rees
DC
,
DeBaun
MR
, et al.
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology commission
.
Lancet Haematol
.
2023
;
10
(
8
):
e633
-
e686
.
12.
Habibi
A
,
Mekontso-Dessap
A
,
Guillaud
C
, et al.
Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes
.
Am J Hematol
.
2016
;
91
(
10
):
989
-
994
.
13.
Pelinski
Y
,
De Luna
G
,
Kassasseya
C
, et al.
DREPADOM - a homecare protocol for vaso-occlusive crisis for sickle cell disease patients
.
Blood
.
2023
;
142
(
Suppl 1
):
793
-
793
.
14.
d'Humières
T
,
Sadraoui
Z
,
Savale
L
, et al.
Atrial arrhythmia in sickle cell anemia adults: A missing link towards understanding and preventing strokes
.
Blood Adv
.
2024
;bloodadvances.2024013208.
15.
Kirkham
JK
,
Estepp
JH
,
Weiss
MJ
,
Rashkin
SR
.
Genetic variation and sickle cell disease severity
.
JAMA Netw Open
.
2023
;
6
(
10
):
e2337484
.
16.
Sheehan
VA
,
Luo
Z
,
Flanagan
JM
, et al.
Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes
.
Am J Hematol
.
2013
;
88
(
7
):
571
-
576
.
17.
Chang
AK
,
Ginter Summarell
CC
,
Birdie
PT
,
Sheehan
VA
.
Genetic modifiers of severity in sickle cell disease
.
Clin Hemorheol Microcirc
.
2018
;
68
(
2-3
):
147
-
164
.
18.
Ilboudo
Y
,
Bartolucci
P
,
Garrett
ME
, et al.
A common functional PIEZO1 deletion allele associates with red blood cell density in sickle cell disease patients
.
Am J Hematol
.
2018
;
93
(
11
):
E362
-
E365
.
19.
Ilboudo
Y
,
Bartolucci
P
,
Rivera
A
, et al.
Genome-wide association study of erythrocyte density in sickle cell disease patients
.
Blood Cells Mol Dis
.
2017
;
65
:
60
-
65
.
20.
Mekontso Dessap
A
,
Contou
D
,
Dandine-Roulland
C
, et al.
Environmental influences on daily emergency admissions in sickle-cell disease patients
.
Medicine (Baltimore)
.
2014
;
93
(
29
):
e280
.
21.
Bartolucci
P
,
Habibi
A
,
Khellaf
M
, et al.
Score predicting acute chest syndrome during vaso-occlusive crises in adult sickle-cell disease patients
.
EBioMedicine
.
2016
;
10
:
305
-
311
.
22.
Voskaridou
E
,
Christoulas
D
,
Bilalis
A
, et al.
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
.
Blood
.
2010
;
115
(
12
):
2354
-
2363
.
23.
Steinberg
MH
,
McCarthy
WF
,
Castro
O
, et al.
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
.
Am J Hematol
.
2010
;
85
(
6
):
403
-
408
.
24.
Tshilolo
L
,
Tomlinson
G
,
Williams
TN
, et al.
Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa
.
N Engl J Med
.
2019
;
380
(
2
):
121
-
131
.
25.
Makani
J
,
Cavazzana
M
,
Gupta
K
, et al.
Blood diseases in Africa: redressing unjust disparities is an urgent unmet need
.
Am J Hematol
.
2022
;
97
(
12
):
1505
-
1506
.
26.
Pressiat
C
,
Rakotoson
M-G
,
Habibi
A
, et al.
Impact of renal function on hydroxyurea exposure in sickle-cell disease patients
.
Br J Clin Pharmacol
.
2021
;
87
(
5
):
2274
-
2285
.
27.
Legrand
T
,
Rakotoson
M-G
,
Galactéros
F
,
Bartolucci
P
,
Hulin
A.
Determination of hydroxyurea in human plasma by HPLC-UV using derivatization with xanthydrol
.
J Chromatogr B Analyt Technol Biomed Life Sci
.
2017
;
1064
:
85
-
91
.
28.
Ware
RE
,
Despotovic
JM
,
Mortier
NA
, et al.
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia
.
Blood
.
2011
;
118
(
18
):
4985
-
4991
.
29.
Lee
MT
,
Piomelli
S
,
Granger
S
, et al.
Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results
.
Blood
.
2006
;
108
(
3
):
847
-
852
.
30.
Gladwin
MT
,
Sachdev
V
,
Jison
ML
, et al.
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease
.
N Eng J Med
.
2004
;
350
(
9
):
886
-
895
.
31.
Parent
F
,
Bachir
D
,
Inamo
J
, et al.
A hemodynamic study of pulmonary hypertension in sickle cell disease
.
N Eng J Med
.
2011
;
365
(
1
):
44
-
53
.
32.
Derebail
VK
,
Ciccone
EJ
,
Zhou
Q
, et al.
Progressive decline in estimated GFR in patients with sickle cell disease: an observational cohort study
.
Am J Kidney Dis
.
2019
;
74
(
1
):
47
-
55
.
33.
Kato
GJ
,
Steinberg
MH
,
Gladwin
MT
.
Intravascular hemolysis and the pathophysiology of sickle cell disease
.
J Clin Invest
.
2017
;
127
(
3
):
750
-
760
.
34.
Ranque
B
,
Diaw
M
,
Dembele
AK
, et al.
Association of haemolysis markers, blood viscosity and microcirculation function with organ damage in sickle cell disease in Sub-Saharan Africa (the BIOCADRE study)
.
Br J Haematol
.
2023
;
203
(
2
):
319
-
326
.
35.
Connes
P
,
Renoux
C
,
Romana
M
, et al.
Blood rheological abnormalities in sickle cell anemia
.
Clin Hemorheol Microcirc
.
2018
;
68
(
2-3
):
165
-
172
.
You do not currently have access to this content.